← All trials
NCT04780035
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2020
- Primary completion
- Aug 31, 2021
- Completion date
- Sep 30, 2021
- First posted
- Mar 3, 2021
- Last posted
- Mar 3, 2021
- Enrollment
- 3000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of RussiaLead sponsor
- Government of RussiaStudy director
- Immanuel Kant Baltic UniversityOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Pirogov Russian National Research Medical UniversityOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Kazan State Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.